Suzuki Masashi, Sasaki Norihito, Miki Takashi, Sakamoto Naoya, Ohmoto-Sekine Yuki, Tamagawa Masaji, Seino Susumu, Marbán Eduardo, Nakaya Haruaki
Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.
J Clin Invest. 2002 Feb;109(4):509-16. doi: 10.1172/JCI14270.
Recently it has been postulated that mitochondrial ATP-sensitive K(+) (mitoK(ATP)) channels rather than sarcolemmal K(ATP) (sarcK(ATP)) channels are important as end effectors and/or triggers of ischemic preconditioning (IPC). To define the pathophysiological significance of sarcK(ATP) channels, we conducted functional experiments using Kir6.2-deficient (KO) mice. Metabolic inhibition with glucose-free, dinitrophenol-containing solution activated sarcK(ATP) current and shortened the action potential duration in ventricular cells isolated from wild-type (WT) but not KO mice. MitoK(ATP) channel function was preserved in KO ventricular cells. In anesthetized mice, IPC reduced the infarct size in WT but not KO mice. Following global ischemia/reperfusion, the increase of left ventricular end-diastolic pressure during ischemia was more marked, and the recovery of contractile function was worse, in KO hearts than in WT hearts. Treatment with HMR1098, a sarcK(ATP) channel blocker, but not 5-hydroxydecanoate, a mitoK(ATP) channel blocker, produced a deterioration of contractile function in WT hearts comparable to that of KO hearts. These findings suggest that sarcKATP channels figures prominently in modulating ischemia/reperfusion injury in the mouse. The rapid heart rate of the mouse (>600 beats per minute) may magnify the relative importance of sarcK(ATP) channels during ischemia, prompting caution in the extrapolation of the conclusions to larger mammals.
最近有人提出,线粒体ATP敏感性钾通道(mitoK(ATP))而非肌膜ATP敏感性钾通道(sarcK(ATP))作为缺血预处理(IPC)的终效应器和/或触发因素更为重要。为了确定sarcK(ATP)通道的病理生理意义,我们使用Kir6.2基因敲除(KO)小鼠进行了功能实验。用无糖、含二硝基苯酚的溶液进行代谢抑制可激活sarcK(ATP)电流,并缩短从野生型(WT)小鼠而非KO小鼠分离的心室细胞的动作电位时程。KO心室细胞中线粒体ATP敏感性钾通道功能得以保留。在麻醉小鼠中,IPC可减小WT小鼠而非KO小鼠的梗死面积。在全心缺血/再灌注后,KO心脏在缺血期间左心室舒张末期压力的升高更为明显,收缩功能的恢复也比WT心脏更差。用sarcK(ATP)通道阻滞剂HMR1098而非线粒体ATP敏感性钾通道阻滞剂5-羟基癸酸处理,可使WT心脏的收缩功能恶化程度与KO心脏相当。这些发现表明,sarcK(ATP)通道在调节小鼠缺血/再灌注损伤中起重要作用。小鼠的快速心率(>600次/分钟)可能会放大缺血期间sarcK(ATP)通道的相对重要性,因此在将这些结论外推至大型哺乳动物时需谨慎。